| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
SFTS virus causes systemic infection accompanied by thrombocytopenia and leukocytopenia in humans, with high motarity rate. The pathogenesis of SFTS virus in humans is poorly understood, and it is desired to establish the animal model and effective antiviral therapies for SFTS. We inoculated SFTS virus to various strains of mice, and evaluated the susceptibility of each mouse strain to SFTS virus infection. Among mouse strains we tested, C3H mice showed remarkable thrombocytopenia and leukocytopenia, especially when infected with SFTS virus intradermally. SFTS virus grew well in spleens of C3H mice, and virus antigen was detected in macrophages of splenic white pulp, showing a “starry sky” appearance.
Furthermore, we examined the efficacies of favipiravir (T-705) and ribavirin against SFTS virus infection in this C3H mouse model. T-705 effectively inhibited the virus growth in mouse spleens, whereas, ribavirin showed little antiviral effect against SFTS virus infection in vivo.
|
